ONC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ONC is not a good buy right now for an impatient entry. The setup is bullish longer-term (strong uptrend + supportive Street targets), but the stock is trading near resistance with RSI stretched and no Intellectia buy signal today—conditions that commonly lead to short-term pullbacks or chop rather than immediate upside. If you must act now, the risk/reward is not attractive versus waiting for a dip closer to ~339–340 (pivot) or a clean breakout above ~356.8 (R2).
Intellectia Proprietary Trading Signals
Trend is bullish: moving averages are stacked positively (SMA_5 > SMA_20 > SMA_200) and MACD histogram is positive and expanding (momentum still building). However, RSI_6 is ~70, which is stretched and often precedes short-term consolidation or a pullback. Key levels: Pivot support ~339.5 (near-term decision area); stronger support ~328.9. Resistance is tight overhead: R1 ~350.2 (near current zone) and R2 ~356.8. With pre-market at ~346.95 (-0.87%), price is still close to resistance while momentum looks a bit extended—more consistent with ‘hold / don’t chase’ than a fresh buy.
Wall Street remains strongly constructive: repeated Buy/Outperform/Overweight ratings and raised price targets (roughly $390–$420 range) imply ~12%–21% upside vs ~347 pre-market.
Commercial execution narrative: analysts highlight Brukinsa strength and guidance tailwinds, supporting a continued revenue ramp.
Pipeline optionality: multiple notes point to meaningful 2026 data/readouts and potential label-expansion/approval catalysts over time.
Technical structure remains in an uptrend (bullish MA stack + positive MACD).
Crowded/extended near-term technicals: RSI ~70 plus price pressing into resistance (R1/R2 zone) increases odds of a pullback or sideways action.
Hedge fund flow is a clear negative: reported hedge funds are selling aggressively (selling amount +7307% QoQ), which can cap near-term momentum.
Profitability deterioration in the latest quarter (net income and EPS down sharply YoY) can keep ‘quality of earnings’ questions in play even with strong revenue growth.
Options positioning is not cleanly bullish: high put open interest (OI put/call 1.
indicates meaningful caution/hedging beneath the surface.
News provided is not a direct ONC catalyst (it centers on Summit Therapeutics/FDA developments), so there is no clear event-driven positive in the summary for ONC specifically.
Latest reported quarter: 2025/Q3. Revenue grew strongly to ~$1.41B (+41% YoY), and gross margin improved to ~86.09% (+3.75% YoY), consistent with a high-margin biotech commercialization profile. However, net income fell to ~$124.8M (-202.88% YoY) and EPS declined to $0.08 (-188.89% YoY), indicating profitability/earnings power weakened materially versus the prior year (likely reflecting higher costs, investment cycle, or one-time impacts despite strong top-line growth).
Recent trend is clearly positive: multiple firms raised price targets and reiterated bullish ratings (Buy/Outperform/Overweight). PTs were lifted from the high-$300s toward ~$400–$420 (Morgan Stanley $405; Jefferies $420; RBC $408; Citi $405; Truist initiation Buy $400; JMP $396). Wall Street pros: strong commercial franchise expectations (Brukinsa), improving guidance narrative, and pipeline upside into 2026. Wall Street cons (implied by the tape/flows rather than downgrades): near-term positioning risk (hedge funds selling), and earnings/profit volatility even with strong revenue growth.
